COMMUNIQUÉ DE PRESSE publié le 24/02/2024 à 15:51 par SANOFI-AVENTIS Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria